Drug
Ciclesonide clinical trials
Also written Alvesco, BI 54903 and Omnaris.
- studies test it
- 64
- open now
- 1
- in phase 3
- 43
- first study started
- 2000
Keep track of what changes. Save the ciclesonide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
64 studies that test it; most in 2011 (10)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 7 |
| 2004 | 9 |
| 2005 | 9 |
| 2006 | 9 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 10 |
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 5 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 11
- Phase 3
- 43
- Phase 4
- 8
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 37
Who runs them
Industry 53 · Other 11
AstraZeneca (34) · Boehringer Ingelheim (8) · Sanofi (4) · Sumitomo Pharma America, Inc. (3) · Covis Pharma S.à.r.l. (2) · University Hospital, Bordeaux (1) · Korea University Guro Hospital (1) · Cantonal Hosptal, Baselland (1)
Often tested with
Tested in the same studies.
Telmisartan (1) · Fluticasone (1) · Azelastine (1) · Tiotropium (1) · Montelukast (1) · Formoterol (1) · Olodaterol (1)
Studies
Open first, then newest update. How each study uses ciclesonide is read from its arms, and is right about nine times in ten.
Testing it · 64
- Inhaled Ciclesonide Study in Preterm InfantsRecruitingPhase 1Venkatesh SampathNCT06589245Written as Alvesco Inhalant Product
- Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for AggravationCompletedPhase 2/3University Hospital, BordeauxNCT04356495Written as Ciclesonide
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).TerminatedPhase 2Boehringer IngelheimNCT01396278Written as BI 54903
- Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)CompletedPhase 4Covis Pharma S.à.r.l.NCT00458835Written as Ciclesonide
- A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 PatientsCompletedPhase 3Covis Pharma S.à.r.l.NCT04377711Written as Ciclesonide
- Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) TherapyTerminatedPhase 2Boehringer IngelheimNCT01397162Written as BI 54903
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)TerminatedPhase 2Boehringer IngelheimNCT01397201Written as BI 54903
- Inhaled Ciclesonide for Outpatients With COVID19TerminatedPhase 2/3McGill University Health Centre/Research Institute of the McGill University Health CentreNCT04435795Written as Ciclesonide
- Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)Status unknownPhase 2Ola Blennow, MD, PhDNCT04381364Written as Ciclesonide Inhalation Aerosol
- A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19CompletedPhase 2Korea University Guro HospitalNCT04330586Written as Ciclesonide Metered Dose Inhaler [Alvesco]
- The Mannitol-Asthma-Ciclesonide-StudyCompletedPhase 4Cantonal Hosptal, BasellandNCT03839433Written as Ciclesonide
- Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)CompletedPhase 3AstraZenecaNCT00163293Written as Ciclesonide
- Effect of High Dose Ciclesonide on Asthma ControlCompletedPhase 3AstraZenecaNCT01455194Written as Ciclesonide
- Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in RussiaCompletedPhase 3AstraZenecaNCT02155881Written as Ciclesonide
- A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With AsthmaCompletedPhase 3AstraZenecaNCT00384189Written as Ciclesonide
- Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)CompletedPhase 3AstraZenecaNCT00306163Written as Ciclesonide
- Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.CompletedPhase 3AstraZenecaNCT00392288Written as Ciclesonide
- Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)CompletedPhase 4AstraZenecaNCT00404547Written as Ciclesonide
- Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)CompletedPhase 3AstraZenecaNCT00163423Written as Ciclesonide
- Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)CompletedPhase 3AstraZenecaNCT00163345Written as Ciclesonide
See all 64 studies that test ciclesonide →
Given in every arm · 1 — ciclesonide is usual care beside what is tested
As the comparator · 4 — what is tested is compared with ciclesonide
- PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -VCompletedPhase 2/3Cambridge University Hospitals NHS Foundation TrustNCT04870333Written as Ciclesonide
- Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female VolunteersCompletedPhase 1Boehringer IngelheimNCT02222428Written as BI 54903 XX
- Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female VolunteersCompletedPhase 1Boehringer IngelheimNCT02220660Written as BI 54903 XX
- A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)CompletedPhase 4Sumitomo Pharma America, Inc.NCT01654536Written as ciclesonide nasal spray
Codes
What other systems call ciclesonide · ClinicalTrials.gg INT004169
- MeSH (NLM) C120481ciclesonideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S59502J185CICLESONIDEConfirmed FDA, NLM, Wikidata
- RxNorm 274964Confirmed FDA, Wikidata
- Wikidata Q5119448ciclesonideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65326CiclesonideOne source FDA
- DrugBank DB01410One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C120481 | ciclesonide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S59502J185 | CICLESONIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 274964 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5119448 | ciclesonide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65326 | Ciclesonide | One source FDA |
| DrugBank | DB01410 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.